Sun Pharmaceutical Industries share price

ABOUT Sun Pharmaceutical Industries

• Industry Biotechnology & Drugs
• ISIN INE044A01036
• BSE Code 524715
• NSE Code SUNPHARMA

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and active pharmaceutical ingredients (APIs). It produces a comprehensive, diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. The Company's vertically integrated network enables it to produce a wide range of pharmaceuticals, including oncology, hormones, peptides, and steroidal drugs. The Company also has a product portfolio in RoW markets, including injectables, hospital products and retail products. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby and Sprinkle portfolio.

Sun Pharmaceutical Industries Management

• C. S. Muralidharan Chief Financial Officer
• Uday Baldota Chief Executive Officer - Taro Pharmaceutical Industries Limited
• S. Damodharan Chief Executive Officer - API Business
• Abhay Gandhi Chief Executive Officer - North America
• Kirti Ganorkar Chief Executive Officer - India Business
• Suresh Rai Chief Human Resource Officer, Senior Vice President
• Dheeraj Sinha Executive Vice President, Chief Information Officer
• Aalok Shanghvi Whole-time Director, Executive Vice-President, Emerging Markets, Global generic R&D, Global BD (Generics Segment) & API
• Jila Breeze Executive Vice President, Global Head - Quality
• Azadar Khan Senior Vice-President, Corporate Relations and Corporate Social Responsibility